Emergence of NDM-producing Pseudomonas aeruginosa among hospitalized patients and impact on antimicrobial therapy during the coronavirus disease 2019 (COVID-19) pandemic

Infect Control Hosp Epidemiol. 2022 Sep;43(9):1279-1280. doi: 10.1017/ice.2021.253. Epub 2021 Jun 28.

Authors

Leandro Reus Rodrigues Perez^{1

2}, Eliana Carniel³, Gabriel Azambuja Narvaez⁴

Affiliations

¹ Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
² Qualitá Laboratory, Novo Hamburgo, Rio Grande do Sul, Brazil.
³ Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil.
⁴ Mãe de Deus Hospital, Porto Alegre, Rio Grande do Sul, Brazil.

PMID: 34184628
DOI: 10.1017/ice.2021.253

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use
COVID-19*
Humans
Microbial Sensitivity Tests
Pandemics
Pseudomonas Infections* / drug therapy
Pseudomonas Infections* / epidemiology
Pseudomonas aeruginosa
beta-Lactamases

Substances

Anti-Bacterial Agents
beta-Lactamases